Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has accepted for filing Irish pharmaceutical firm Actavis' new drug application (NDA) for eluxadoline, an investigational drug to treat diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome (IBS-D).
Subscribe to our email newsletter
The NDA is based on the results of two Phase III clinical trials that met their primary endpoints.
The 12-week efficacy portion of the trials showed significant superiority over placebo in the composite endpoint of the simultaneous improvement in both pain and diarrhea at both 75mg and 100mg doses.
Actavis subsidiary Furiex Pharmaceuticals senior vice president of Clinical Operations and Development Paul Covington said the NDA filing of eluxadoline marks an important step forward for this potential first-in-class treatment, which shows the company’s commitment to helping patients suffering from this debilitating condition.
"We are pleased that the FDA has granted eluxadoline a priority review, setting the stage for us to bring this potential new treatment option to patients promptly," Covington said.
Around 2,500 patients were involved in these trials, which showed that eluxadoline was well-tolerated, and the adverse events included constipation, nausea and abdominal pain.
The company is focused in developing and manufacturing generic, brand, branded generic, legacy brands and over-the-counter (OTC) pharmaceutical products and has commercial operations in about 60 countries.